Companies › Ausper Biopharma
2 active drug programs in 9 registered trials: 6 Phase 2, 2 Phase 1, 1 Phase 3; Infectious disease; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| AHB-137 Immunomodulator for hepatitis B | – | Phase 3 | Chronic Hepatitis B | Dec 2026 |
| AHB-171 Injection | – | Phase 2 | Hepatitis B, Chronic (CHB); Chronic Hepatitis B Infection | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07137910 | AHB-137 | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT06829329 | AHB-137 | Phase 2 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT07246889 | AHB-137 | Phase 3 | Chronic Hepatitis B | Infectious disease | Dec 2026 |
| NCT07635186 | AHB-137 | Phase 2 | Chronic Hepatitis B | Infectious disease | Jun 2027 |
| NCT07069569 | AHB-137 | Phase 2 | Chronic Hepatitis B | Infectious disease | Jul 2027 |
| NCT06993480 | AHB-137 | Phase 2 | Chronic Hepatitis B | Infectious disease | Jul 2027 |
| NCT07511218 | AHB-171 Injection | Phase 1 | Chronic Hepatitis B Infection | Infectious disease | Dec 2027 |
| NCT07600788 | AHB-137 | Phase 1 | Chronic Hepatitis B | Infectious disease | May 2028 |
| NCT07630727 | AHB-171 Injection | Phase 2 | Hepatitis B, Chronic (CHB) | Infectious disease | Mar 2029 |
No annotated target.
–
Fujian Akeylink Biotechnology Laboratorio Farmaceutico SIT srl Amplexd Therapeutics Sano Chemicals Hyundai Bioscience
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.